Scilex Holding (SCLX) Q3 2024 earnings summary

Executive summary

• Net revenue for Q3 2024 was $14.4 million, up 43% year-over-year, driven by ELYXYB sales growth and the launch of GLOPERBA in June 2024.

• Net loss for Q3 2024 was $4.4 million, a significant improvement from a $35.5 million loss in Q3 2023, due to higher revenue, lower operating expenses, and gains on derivative liabilities.

• The company remains heavily dependent on ZTlido, with ELYXYB and GLOPERBA in early commercialization stages.

• Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to negative working capital and low cash balances.

Financial highlights

• Net revenue for the nine months ended September 30, 2024 was $41.7 million, up from $33.3 million in the prior year period.

• Net loss for the nine months ended September 30, 2024 was $66.3 million, improved from $92.9 million in the prior year.

• Cash and cash equivalents as of September 30, 2024 were approximately $0.1 million.

• Total indebtedness as of September 30, 2024 was $102.0 million, including $69.9 million on the Oramed Note, $14.7 million FSF Deposit, and $14.3 million Revolving Facility.

• Operating cash flow for the nine months ended September 30, 2024 was $16.8 million, compared to negative $15.3 million in the prior year.

Outlook and guidance

• The company expects continued investment in sales, marketing, and R&D for ZTlido, GLOPERBA, ELYXYB, and pipeline candidates.

• Management anticipates the need for substantial additional funding to support operations and growth strategy.

• Plans to seek additional capital through equity, debt, collaborations, or strategic transactions.

• Substantial doubt remains about the ability to continue as a going concern for the next 12 months.